Invectys

Focus: Invectys is a French biotechnology company focused on DNA vaccine development for infectious diseases and vaccine applications. The company operates as a specialized biotech player in the emerging DNA vaccine space.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Invectys

AI assessmentNot Hiring

No open roles listed right now. Follow Invectys to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT04515043EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

Phase 1

Help build intelligence for Invectys

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in DNA vaccines, an emerging modality with significant unmet need in infectious diseases
France-based location offers access to European biotech ecosystem and regulatory expertise
Early-stage company provides potential for significant career impact and equity upside in a specialized field

Watch Out For

No active job openings currently listed, indicating limited near-term hiring
Missing critical data on funding, stage, employee count, and clinical progress creates visibility gaps on company stability and trajectory

Generated by Claude from Invectys's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

INVAC-1

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02301754INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

Phase 1

Single Injection of IVS-3001- Anti - HLA-G CAR-T cells

Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05672459A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Phase 1/2

UCPVax

Metastatic Non-small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT02818426Universal Cancer Peptide-based Vaccination in Metastatic NSCLC

Phase 1/2

INVAC-1

Leukemia, Lymphocytic, Chronic, B-Cell

Phase 2

Clinical Trials (1)

NCT03265717DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline